Trial · NCT03201900
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel | Perampanel | 63.0 | 95% Confidence Interval 50.9 to 74.0 | percentage of participants | |
| Percentage of Participants With POS Who Achieved Seizure-free Status During the 26-week Maintenance Period of Last Evaluated Dose of 4 or 8 mg Perampanel | Perampanel | 74.0 | 95% Confidence Interval 62.4 to 83.5 | percentage of participants | |
| Percentage of Participants With POS Who Achieved Seizure-free Status During the 52-week Treatment Phase (26-week Maintenance Period Plus 26-week Extension Phase) of 4 mg of Perampanel | Perampanel | 32.9 | 95% Confidence Interval 22.3 to 44.9 | percentage of participants | |
Percentage of Participants With POS Who Achieved Seizure-free Status During the 52-week of Treatment Phase (26-week Maintenance Period Plus 26-week Extension Phase) of Last Evaluated Dose of 4 or 8 mg Perampanel | Perampanel | 42.5 | 95% Confidence Interval 31.0 to 54.6 | percentage of participants | |
| Time to Onset of First Seizure From the First Dose of Study Drug in the Maintenance Period of 4 mg Perampanel | Perampanel | NA | 95% Confidence Interval 37.4 to NA | weeks | |
| Time to Onset of First Seizure From the First Dose of Study Drug in the Maintenance Period of Last Evaluated Dose of 4 or 8 mg Perampanel | Perampanel | NA | 95% Confidence Interval NA to NA | weeks | |
| Time to Withdrawal From the First Dose of Study Drug in the Maintenance Period of 4 mg Perampanel | Perampanel | NA | 95% Confidence Interval 27.4 to NA | weeks | |
| Time to Withdrawal From the First Dose of Study Drug in the Maintenance Period of Last Evaluated Dose of 4 or 8 mg Perampanel | Perampanel | NA | 95% Confidence Interval 27.4 to NA | weeks | |
| Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Event (TESAEs), and TEAEs Leading to Discontinuation of the Study Drug | Perampanel | TEAEs | 74 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Event (TESAEs), and TEAEs Leading to Discontinuation of the Study Drug | Perampanel | TESAEs | 13 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Event (TESAEs), and TEAEs Leading to Discontinuation of the Study Drug | Perampanel | TEAEs leading to discontinuation of study drug | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03201900/results